Novavax (NVAX) Cash from Financing Activities (2010 - 2026)

Novavax's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $37.7 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 633.56% year-over-year to $37.7 million in Q1 2026; TTM through Mar 2026 was $72.5 million, a 70.73% decrease from a year earlier, with the FY2025 full-year figure at $27.7 million, down 89.36% from the prior year.
• Cash from Financing Activities advanced to $37.7 million in Q1 2026 per NVAX's latest filing, from -$6.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $258.2 million in Q2 2024 and bottomed at -$354.4 million in Q1 2023.
• The 5-year median for Cash from Financing Activities is $5.9 million (2024), against an average of $38.6 million.
• Across the five-year window, Cash from Financing Activities plunged 321.67% in 2023 and jumped 43854.64% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $191.4 million in 2022, then sank by 47.56% to $100.4 million in 2023, then tumbled by 103.41% to -$3.4 million in 2024, then sank by 92.99% to -$6.6 million in 2025, then surged by 670.49% to $37.7 million in 2026.
• Per Business Quant, the three latest NVAX Cash from Financing Activities figures stand at $37.7 million (Q1 2026), -$6.6 million (Q4 2025), and $42.4 million (Q3 2025).